Vamikibart for Diabetic Macular Edema

Vamikibart for Diabetic Macular Edema
82%63%43%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12Apr 26 • YES 52.0%Apr 27 • YES 62.0%Apr 28 • YES 62.2%Apr 29 • YES 75.7%Apr 30 • YES 75.7%May 1 • YES 75.7%May 2 • YES 75.7%May 3 • YES 75.7%May 4 • YES 76.0%May 5 • YES 76.0%May 7 • YES 49.5%May 11 • YES 49.5%May 12 • YES 49.5%
Hoffmann-La Roche ($RHHBY)
No stock closeNo stock close$51.85$50.96$50.06Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12Apr 27 • RHHBY $51.22Apr 28 • RHHBY $51.04Apr 29 • RHHBY $50.43Apr 30 • RHHBY $50.88May 1 • RHHBY $51.00May 4 • RHHBY $50.28May 5 • RHHBY $50.84May 6 • RHHBY $51.63May 7 • RHHBY $50.59May 8 • RHHBY $51.09May 11 • RHHBY $51.41May 12 • RHHBY $51.18

Will this trial show a positive result on mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants, Baseline, Week 44 and Week 48?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
Primary Completion
11/6/24
Study Completion
4/21/25
Sponsor
Hoffmann-La Roche
Ticker
$RHHBY
Type
Phase 2
Trial Status
Completed
Trial Size
394
NCT
NCT05151731
Trial Description
This Phase 2 trial tested vamikibart eye injections for diabetic macular edema, measuring changes in best corrected vision at Weeks 44 and 48.